Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Recommend Technology Appraisals

Service notifications for recommended Technology Appraisals (TAs)

Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.

Title	Description	Date added	Download
TA837	Overview \| Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma \| Guidance \| NICE	18-01-2023	Download Preview
TA836	Overview \| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy \| Guidance \| NICE	18-01-2023	Download Preview
TA835	Overview \| Fostamatinib for treating refractory chronic immune thrombocytopenia \| Guidance \| NICE	18-01-2023	Download Preview
TA833	Overview \| Zanubrutinib for treating Waldenstrom’s macroglobulinaemia \| Guidance \| NICE	18-01-2023	Download Preview
TA832	Overview \| Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids \| Guidance \| NICE	19-12-2022	Download Preview
TA830	Overview \| Pembrolizumab for adjuvant treatment of renal cell carcinoma \| Guidance \| NICE	18-01-2023	Download Preview
TA829	Overview \| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy \| Guidance \| NICE	18-01-2023	Download Preview
TA828	Overview \| Ozanimod for treating moderately to severely active ulcerative colitis \| Guidance \| NICE	18-01-2023	Download Preview
TA827	Overview \| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy \| Guidance \| NICE	18-01-2023	Download Preview
TA824	Overview \| Dexamethasone intravitreal implant for treating diabetic macular oedema \| Guidance \| NICE	18-01-2023	Download Preview
TA823	Overview \| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer \| Guidance \| NICE	18-01-2023	Download Preview
TA821	Overview \| Avalglucosidase alfa for treating Pompe disease \| Guidance \| NICE	18-01-2023	Download Preview
TA813	Overview \| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors \| Guidance \| NICE	18-01-2023	Download Preview
TA810	Overview \| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence \| Guidance \| NICE	18-01-2023	Download Preview
TA809	Overview \| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease \| Guidance \| NICE	18-01-2023	Download Preview
TA808	Overview \| Fenfluramine for treating seizures associated with Dravet syndrome \| Guidance \| NICE	18-01-2023	Download Preview
TA805	Overview \| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides \| Guidance \| NICE	19-12-2022	Download Preview
TA803	Overview \| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs \| Guidance \| NICE	18-01-2023	Download Preview
TA802	Overview \| Cemiplimab for treating advanced cutaneous squamous cell carcinoma \| Guidance \| NICE	18-01-2023	Download Preview
TA801	Overview \| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer \| Guidance \| NICE	18-01-2023	Download Preview

1 2 3 … 20 Next »

NICE Ref		Title	Date Issued by HSCB
TA234		Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	05/01/2012
TA233		Golimumab for the treatment of ankylosing spondylitis	20/02/2012
TA232		Retigabine for the adjunctive treatment of partial onset seizures in epilepsy	05/01/2012
TA230		Bivalirudin for the treatment of ST-segment-elevation myocardial infarction	05/01/2012
TA229		Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion	05/01/2012
TA228		Bortezomib and thalidomide for the firstline treatment of multiple myeloma	05/01/2012
TA227		Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer	05/01/2012
TA226		Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma	05/01/2012
TA225		Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs	20/02/2012
TA223		Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease	05/01/2012
TA222		Trabectedin for the treatment of relapsed ovarian cancer	05/01/2012
TA221		Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura	05/01/2012
TA220		Golimumab for the treatment of psoriatic arthritis	20/02/2012
TA216		Bendamustine for the first-line treatment of chronic lymphocytic leukaemia	05/01/2012
TA215		Pazopanib for the first-line treatment of advanced renal cell carcinoma	05/01/2012
TA208		Trastuzumab for the treatment of HER2-positive metastatic gastric cancer	05/01/2012
TA203		Liraglutide for the treatment of type 2 diabetes mellitus	20/02/2012
TA200		Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C	05/01/2012
TA199	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis		20/02/2012
TA198	Tocilizumab for the treatment of rheumatoid arthritis		05/01/2012
TA197	Dronedarone for the treatment of non-permanent atrial fibrillation		20/02/2012
TA195	Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor		05/01/2012
TA193	Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia		05/01/2012
TA190	Pemetrexed for the maintenance treatment of non-small-cell lung cancer		05/01/2012
TA188	Human growth hormone (somatropin) for the treatment of growth failure in children		05/01/2012
TA187	Infliximab (review) and adalimumab for the treatment of Crohn’s disease		05/01/2012
TA186	Certolizumab pegol for the treatment of rheumatoid arthritis		20/02/2012
TA169	Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma		05/01/2012
TA166	Cochlear implants for children and adults with severe to profound deafness		05/01/2012
TA98	Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents		14/09/2016
TA75	Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C		05/01/2012
TA23	Temozolomide for the treatment of recurrent malignant gliomaC		02/08/2016
TA20	Riluzole for the treatment of Motor Neurone Disease		01/08/2016

Quick Links

Contents